Feasibility of a streamlined imaging protocol in technetium-99m-Tektrotyd somatostatin receptor SPECT/CT.

Published on Jun 1, 2018in Clinical Radiology2.118
· DOI :10.1016/J.CRAD.2017.12.019
H. Al-Chalabi1
Estimated H-index: 1
(Leeds Teaching Hospitals NHS Trust),
A.M. Cook1
Estimated H-index: 1
(Leeds Teaching Hospitals NHS Trust)
+ 2 AuthorsAndrew Scarsbrook29
Estimated H-index: 29
(Leeds Teaching Hospitals NHS Trust)
Sources
Abstract
Aim To assess the feasibility and efficacy of a streamlined single time-point 99mTc-HYNIC-Tyr3-octreotide (Tektrotyd) somatostatin receptor scintigraphy (SRS) protocol to differentiate pathological uptake by neuroendocrine tumours (NETs) from physiological activity. Methods and materials Tektrotyd imaging in 50 consecutive patients with NETs was reviewed retrospectively. Imaging was independently assessed by two experienced reporters with dual-certification in radiology and nuclear medicine and agreed in consensus. The presence of physiological bowel activity and/or further sites of equivocal uptake on 4-hour planar imaging and whether combined single-photon-emission computed tomography (SPECT)/computed tomography (CT) assessment allowed accurate diagnosis was tabulated. A judgement was also made in each case on whether 2-hour planar imaging was necessary for accurate diagnostic interpretation. Results Thirty-six patients (72%) had positive findings on Tektrotyd SPECT/CT. Eight patients (16%) had bowel activity on 4-hour planar imaging, which could be considered to have hampered interpretation without access to SPECT/CT. Eleven studies in 10 patients (20%) demonstrated areas of indeterminate uptake on planar imaging; five in the uncinate process of the pancreas, three in the nasal cavity or paranasal sinuses, one in the adrenal glands, one in a focus of inflammation on the posterior abdominal wall, and one at the tip of a central venous line. In all cases, accurate interpretation of findings was possible with SPECT/CT, without the 2-hour planar image. Conclusion Two-hour planar imaging could be safely omitted from Tektrotyd SRS incorporating SPECT/CT imaging without reducing the accuracy of diagnostic interpretation. Streamlined imaging has the potential to reduce patient inconvenience and improve scanner and staff efficiency.
📖 Papers frequently viewed together
92 Citations
1 Citations
2015
2 Authors (Xuehui Liu, Hongjun Li)
References22
Newest
#1Amel Ait Boudaoud ('ENS Paris': École Normale Supérieure)H-Index: 1
#2Bruno VergèsH-Index: 56
Last. Olivier HumbertH-Index: 12
view all 6 authors...
The aim of this study was to assess the relevance of physiological 111In-octreotide uptake in the head of pancreas and to establish its imaging features in comparison with pathological uptake in patients with neuroendocrine tumors (NET). We retrospectively reviewed all patients that underwent 111In-octreotide single-photon emission tomography (SPECT) scintigraphy in our institution. Only patients with an isolated uptake in the head of the pancreas were included. 111In-octreotidescintigraphy cons...
5 CitationsSource
ObjectivesThe aim of this study was to conduct a nationwide survey of computed tomography (CT) doses for a wide range of PET-CT and single photon emission computed tomography-computed tomography (SPECT-CT) imaging procedures, with the aim of generating proposed UK national diagnostic reference level
22 CitationsSource
#1Tessa BrabanderH-Index: 11
#2Jaap J.M. TeunissenH-Index: 28
Last. Dirk Jan KwekkeboomH-Index: 53
view all 3 authors...
PURPOSE: Physiological uptake in the uncinate process or pancreatic head has been described with Ga-labeled PET tracers for somatostatin receptor imaging. In-DTPA-octreotide is the only registered radiopharmaceutical for the imaging of neuroendocrine tumors. We studied the uptake in this region of the pancreatic head on somatostatin receptor scintigraphy (SRS) using In-DTPA-octreotide in a large group of patients. Furthermore, known physiological and clinical characteristics are discussed in an ...
7 CitationsSource
#1Helen AndrewH-Index: 1
#2Gemma GossedgeH-Index: 3
Last. David JayneH-Index: 25
view all 10 authors...
653 Citations
#1Andrew Scarsbrook (St James's University Hospital)H-Index: 29
#2Sally Barrington (St Thomas' Hospital)H-Index: 52
Combined positron-emission tomography and computed tomography (PET-CT) has taken the oncological world by storm since being introduced into the clinical domain in the early 21st century and is firmly established in the management pathway of many different tumour types. Non-oncological applications of PET-CT represent a smaller but steadily growing area of interest. PET-CT continues to be the focus of a large number of research studies and keeping up-to-date with the literature is important but r...
9 CitationsSource
#1Juri RufH-Index: 15
Last. Holger AmthauerH-Index: 45
view all 13 authors...
This prospective study compared a 1-d SPECT/CT protocol with the commonly used 3-d protocol for somatostatin receptor scintigraphy in patients with gastroenteropancreatic neuroendocrine neoplasms. Additionally, the influence of SPECT/CT on patient management was evaluated.From October 2011 to October 2012, all gastroenteropancreatic neuroendocrine neoplasm patients undergoing restaging with somatostatin receptor scintigraphy on a modern SPECT/CT device were enrolled in this study. The protocol c...
3 CitationsSource
#1Vera Artiko (University of Belgrade)H-Index: 12
#2Aida AfganH-Index: 1
Last. Vladimir Obradović (University of Belgrade)H-Index: 11
view all 8 authors...
BACKGROUND: This paper is the short review of our preliminary results obtained with 99mTc-EDDA/HYNIC-TOC. MATERIAL AND METHODS: The total of 495 patients with different neuroendocrine tumors were investigated during last few years. RESULTS: There have been 334 true positive (TP), 73 true negative (TN), 6 false positive (FP) and 82 false negative findings (FN). Diagnosis was made according to SPECT findings in 122 patients (25%). The mean T/NT ratio for TP cases was significantly higher (p < 0.01...
12 CitationsSource
#1Ildikó Garai (University of Debrecen)H-Index: 13
#2Sándor BarnaH-Index: 6
Last. Attila ForgácsH-Index: 12
view all 4 authors...
Tektrotyd kit was developed by Polatom company for 99mTc labeling to make an alternative tracer of somatostatin receptor scintigraphy available. Since 2005, 99mTc-EDDA/HYNIC-Tyr3-Octreotide has been used in clinical imaging and achieved high impact in management of patients with neuroendocrine tumors. Knowing the limitations and pitfalls is essential to provide ac­curate diagnosis. Therefore, the potential pitfalls associated with the use of 99mTc-EDDA/HYNIC-TOC are reviewed on the basis of own ...
9 CitationsSource
We have come a long way in our understanding and treatment of neuroendocrine tumors since the term “karzinoide” was coined in 1907. Neuroendocrine tumors are a group of biologically and clinically heterogeneous neoplasms that most commonly originate in the lungs, GI tract, and pancreas. The selection of initial and subsequent therapies requires careful consideration of both tumor and treatment characteristics. With recent advances, we now have more tools for the diagnosis and treatment of our pa...
83 CitationsSource
Purpose Neuroendocrine tumours (NET) are uncommon and may be localized in many different places in the body. Traditional imaging has mainly been performed with CT and somatostatin receptor scintigraphy (SRS). Recently, it has become possible to use somatostatin receptor PET/CT (SMSR PET) instead, which might improve diagnostic quality. To evaluate the diagnostic quality of SMSR PET we performed a meta-analysis as an update of a previous study published in 2012.
100 CitationsSource
Cited By1
Newest
view all 7 authors...
Source